Polaryx Therapeutics, Inc. Common Stock (PLYX)

US — Healthcare Sector
Peers: ANTX  CBIO  FHTX  HCWB  JBIO  KLRS  KZR  LYEL  NXTC  PTHS 

Automate Your Wheel Strategy on PLYX

With Tiblio's Option Bot, you can configure your own wheel strategy including PLYX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
PLYX
Published: February 27, 2026 by: GlobeNewsWire
Sentiment: Neutral

PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), joins the global rare disease community in raising awareness and supporting patients, families, caregivers, and healthcare providers.

Read More
image for news Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
PLYX
Published: February 10, 2026 by: GlobeNewsWire
Sentiment: Neutral

PARAMUS, NJ, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announced that the late-breaking presentation of new data for PLX-200, an investigational therapy for the treatment of Krabbe disease (globoid cell leukodystrophy) at the 22nd Annual WORLDSymposium™, was given on February 6, 2026 in San Diego, Calif. Key Findings and Scientific Perspective At the Contemporary Forum, Late-breaking Science and the Rapid Fire Competition, Shrijay Vijayan, Ph.D.

Read More
image for news Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
PLYX
Published: February 03, 2026 by: GlobeNewsWire
Sentiment: Neutral

Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug candidate PLX-200 Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug candidate PLX-200

Read More
image for news Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch

About Polaryx Therapeutics, Inc. Common Stock (PLYX)

  • IPO Date 2026-02-02
  • Website https://polaryx.com
  • Industry Biotechnology
  • CEO Alex Yang
  • Employees 11
Polaryx Therapeutics, Inc., operates as a biotech company that develops small molecule therapeutics for lysosomal storage disorders and neurodegenerative disorders. Its pipeline includes PLX-100, a combination of PLX-200 and a supplement for late infantile neuronal ceroid lipofuscinosis (LINCL) and other forms of NCL; PLX-200, a repurposed drug that is used to treat other diseases in adults and children; and PLX-300, a drug isolated from an edible plant that activates PPARa, which enhances production of transcription factor EB. The company was founded in 2014 and is based in Paramus, New Jersey.